E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute myeloid leukemia and severe myelodysplastic syndrome and chronic myelomonocytic leukemia |
|
E.1.1.1 | Medical condition in easily understood language |
Acute myeloid leukemia and severe myelodysplastic syndrome and chronic myelomonocytic leukemia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the cost-effectiveness of a precision therapy strategy compared with standard treatment. |
|
E.2.2 | Secondary objectives of the trial |
To investigate if precision therapy improves event free survival (EFS) in unfit elderly patients with AML or MDS. To investigate if precision therapy improves overall survival in unfit elderly patients with AML or MDS. To set up a diagnostic pipeline, based on the previous MetAction study pipeline, for personalized diagnostics of unfit elderly patients with AML and MDS. To evaluate the safety of precision therapy in unfit elderly patients with MDS or AML. To determine the efficacy profile of the different treatments: Transfusion independence, response rate (CR, CRi, PR). To identify how treatments influence health related quality of life (HRQoL) To estimate the budget impact of providing targeted treatment to all eligible elderly AML and MDS patients
To investigate molecular mechanisms for the evolvement from MDS to AML. To evaluate the prognostic value of baseline physical and functional conditions using geriatric assessment tool G8.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients with: - a diagnosis of AML and related precursor neoplasms according to WHO 2016 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease and therapy-related AML (not if they have received antileukemic/mds treatment)), or - acute leukemias of ambiguous lineage according to WHO 2016 or - a diagnosis of myelodysplastic syndrome (MDS) with IPSS-R > 4.5.1 • Patients 60 years and older. • Patients must NOT be eligible for intensive chemotherapy or allogeneic stem cell therapy (See Chapter 23.3) • WBC ≤ 25 x109/L (prior hydroxyurea allowed for a maximum of 14 days, stopped before start of treatment) • Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values: - Serum creatinine ≤ 2.5 mg/dL (≤ 221.7 μmol/L), unless considered AML-related - Serum bilirubin ≤ 2.5 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert’s syndrome - Alanine transaminase (ALT) ≤ 2.5 x ULN, unless considered AML-related • WHO performance status 0, 1 or 2 for subjects ≥ 75 years of age OR 0 to 3 for subjects ≥ 60 to 74 years of age. • Life-expectancy above 3 months • Signed Informed Conscent • Male Subjects Only: Male subjects who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration until at least 90 days after the last dose of study drug.
|
|
E.4 | Principal exclusion criteria |
• Acute promyelocytic leukemia. • AML with favourable cytogenetic or genetic changes in patients who are fit for intensive chemotherapy. Favourable genetics are: t(8;21)(q22;q22.1); RUNX1-RUNX1T1; inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11; mutated NPM1 without FLT3-ITD or with FLT3-ITDlow†; Biallelic mutated CEBPA • Patients previously treated for AML or MDS (any antileukemic therapy or MDS treatment including investigational agents). • Patients where it is not possible to get bone-marrow for NGS, i.e., “dry tap”. • Diagnosis of any previous or concomitant malignancy is an exclusion criterion: except when the patient completed successfully treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 6 months prior to randomization. • Blast crisis of chronic myeloid leukemia. • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.) • Cardiac dysfunction as defined by: o Unstable angina or o New York Heart Association Class ≥ 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or angina pain or o Unstable cardiac arrhythmias • Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance with the study protocol and follow-up schedule. • Patients who have senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent. • Patients who do not understand the Written Informed Consent (e.g., language problems) • Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea. • Subject is known to be positive for HIV (HIV testing is not required). • Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required). Subjects with serologic evidence of prior vaccination to HBV [ie. HBs Ag-, and anti-HBs+] may participate. • AML subjects that has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of venetoclax treatment. • AML subject that has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of venetoclax treatment. • Subject has a malabsorption syndrome or other condition that precludes enteral route of administration.
Additional exclusion criteria at the time of randomization • WHO performance status > 2 for subjects ≥ 75 years of age OR > 3 for subjects ≥ 60 to 74 years of age. • Progressive disease according to ELN criteria (see chapter 12 Response evaluation) • Initial treatment has made the patient eligible for allogeneic stem-cell transplantation • In addition, it will be specific exclusion criteria for the patients receiving targeted therapies related to the Summary of Product Characteristics (SPC) of each drug. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Median event free survival, i.e., the number of days to death or progression of the disease (whichever comes first). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Median overall survival. • Cumulative rate of overall response rate after 6 months and 12 months treatment. haematological remission and adverse events 24 months after study entry. • Transfusion independence of erythrocytes • Transfusion independence of thrombocytes • Median event free survival and overall survival in patients who received targeted therapy compared with standard therapy, irrespective of randomization. • Median event free survival in AML compared with MDS. • Health-related quality of life (HRQoL) • Total costs of treatment and follow-up • Cost-effectiveness of precison therapy, defined by the incremental costs per quality adjusted life-years gained (QALYs) • Budget impact of providing targeted treatment to all eligible patients • Toxicity defined as the number of adverse events with CTCAE grade 2 or more by treatment arm and by treatments in the precision therapy arm.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |